Suggested remit: To appraise the clinical and cost effectiveness of amivantamab in combination with carboplatin and pemetrexed within its marketing authorisation for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 5110
Provisional Schedule
- Committee meeting: 2:
- 13 August 2025
- Expected publication:
- 23 October 2025
Project Team
- Project lead
- Jen Upton
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Johnson and Johnson (amivantamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- EGFR Positive UK
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Amarox (erlotinib) (confidentiality agreement not signed, not participating)
- Aspire pharma (pemetrexed) (confidentiality agreement not signed, not participating)
- AstraZeneca (gefitinib, osimertinib) (confidentiality agreement signed, participating)
- Boehringer Ingelheim (afatinib) (confidentiality agreement not signed, not participating)
- Bristol Myers Squibb (paclitaxel) (confidentiality agreement not signed, not participating)
- Cipla EU (gefitinib) (confidentiality agreement not signed, not participating)
- Eli Lilly and company (pemetrexed) (confidentiality agreement not signed, not participating)
- Genus pharmaceuticals (pemetrexed, gefitinib) (confidentiality agreement not signed, not participating)
- Glenmark Pharmaceutical (erlotinib) (confidentiality agreement not signed, not participating)
- Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
- Medac GmbH (vinorelbine) (confidentiality agreement not signed, not participating)
- Merck, Sharp & Dohme (pembrolizumab) (confidentiality agreement signed, participating)
- Mylan (erlotinib) (confidentiality agreement not signed, not participating)
- Pfizer (pemetrexed, dacomitinib) (confidentiality agreement signed, participating)
- Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
- Roche (atezolizumab, erlotinib) (confidentiality agreement signed, participating)
- Sandoz (cisplatin, docetaxel, pemetrexed, erlotinib, gefitinib) (confidentiality agreement not signed, not participating)
- Seacross pharmaceuticals (docetaxel, paclitaxel, pemetrexed) (confidentiality agreement not signed, not participating)
- Sun Pharmaceuticals (gemcitabine, pemetrexed) (confidentiality agreement not signed, not participating)
- Synchrony Pharma (gemcitabine) (confidentiality agreement not signed, not participating)
- Teva UK (paclitaxel) (confidentiality agreement not signed, not participating)
- Zentiva (pemetrexed, erlotinib) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 March 2025 - 24 April 2025 | Draft guidance |
| 28 March 2025 | The second committee meeting for this topic has now been scheduled for Wednesday 13 August 2025. This is to ensure Johnson & Johnson Innovative Medicine and all other stakeholders have sufficient time to review the Draft Guidance and provide the full evidence needed to inform the committee’s recommendations |
| 12 February 2025 | Committee meeting |
| 12 February 2025 | Declaration of interests |
| 10 July 2024 | Invitation to participate |
| 23 May 2024 - 21 June 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5110 |
| 23 May 2024 | In progress. Scoping commenced. |
| 30 November 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled. We now anticipate that the appraisal will begin during mid-July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2024. |
| 04 May 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 April 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 April 2022 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual